<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ezogabine (retigabine) (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ezogabine (retigabine) (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ezogabine (retigabine) (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="17071" href="/d/html/17071.html" rel="external">see "Ezogabine (retigabine) (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F21857918"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Retinal abnormalities and potential vision loss:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;"> Ezogabine can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss. In addition, macular abnormalities characterized as vitelliform lesions have been observed. These lesions have been identified most consistently with optical coherence tomography imaging.</p>
<p style="text-indent:-2em;margin-left:2em;">Some patients with retinal abnormalities have been found to have abnormal visual acuity. It is not possible to determine whether ezogabine caused this decreased visual acuity, because baseline assessments are not available for these patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Approximately one-third of the patients who had eye examinations performed after approximately 4 years of treatment were found to have retinal pigmentary abnormalities. An earlier onset cannot be ruled out, and it is possible that retinal abnormalities were present earlier in the course of exposure to ezogabine. The rate of progression of retinal abnormalities and their reversibility are unknown. Reversibility of retinal pigmentary abnormalities and partial resolution of vitelliform lesions has been reported after discontinuation of ezogabine in some patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Only use ezogabine in patients who have responded inadequately to several alternative treatments and for whom the benefits outweigh the potential risk of vision loss. Patients who fail to show substantial clinical benefit after adequate titration should be discontinued from ezogabine.</p>
<p style="text-indent:-2em;margin-left:2em;">All patients taking ezogabine should have baseline and periodic (every 6 months) systematic visual monitoring by an ophthalmic professional. Testing should include visual acuity, dilated fundus photography, and optical coherence tomography. Additional testing may include fluorescein angiograms, perimetry, and electroretinograms (ERG).</p>
<p style="text-indent:-2em;margin-left:2em;">If retinal pigmentary abnormalities or vision changes are detected, discontinue therapy unless no other suitable treatment options are available and the benefits of treatment outweigh the potential risk of vision loss.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F12915691"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Neuronal Potassium Channel Opener</li></ul></div>
<div class="block doa drugH1Div" id="F13371903"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Potiga has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9064b26-8a67-479f-af28-aa1b3376c388">Partial-onset seizures, adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Partial-onset seizures, adjunct:</b>
<b>Oral:</b> Initial: 100 mg 3 times daily; may increase at weekly intervals in increments of ≤150 mg per day to a maintenance dose of 200 to 400 mg 3 times daily based on tolerability (maximum: 400 mg 3 times daily [1,200 mg per day]). In clinical trials, no additional benefit and an increase in adverse effects was observed with doses &gt;900 mg per day. <b>Note:</b> If there is no substantial benefit after adequate titration, then discontinue use and consider other treatment options.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991096"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute: Initial: 50 mg 3 times daily; may increase at weekly intervals in increments of ≤150 mg  per day to a maximum dose of 200 mg 3 times daily (600 mg per day).</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD requiring hemodialysis: Initial: 50 mg 3 times daily; may increase at weekly intervals in increments of ≤150 mg per day to a maximum dose of 200 mg 3 times daily (600 mg per day). <b>Note:</b> Immediately following hemodialysis a single supplemental dose is recommended; if break through seizures occur toward the end of hemodialysis, an additional supplemental dose may be considered at the start of subsequent dialysis sessions.</p></div>
<div class="block doha drugH1Div" id="F50988381"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh 5 to 6): No dosage adjustment  necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh 7 to 9): Initial: 50 mg 3 times daily; may increase at weekly intervals in increments of ≤150 mg per day to a maximum dose of 250 mg 3 times daily (750 mg per day). </p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh &gt;9): Initial: 50 mg 3 times daily; may increase at weekly intervals in increment of ≤150 mg per day to a maximum dose of 200 mg 3 times daily (600 mg per day). </p></div>
<div class="block doe drugH1Div" id="F13371899"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Partial-onset seizures, adjunct:</b> Oral: Initial: 50 mg 3 times daily; may increase at weekly intervals in increments of ≤150 mg per day to a maximum dose of 250 mg 3 times daily (750 mg per day). <b>Note:</b> If there is no substantial benefit after adequate titration, then discontinue use and consider other treatment options.</p></div>
<div class="block adr drugH1Div" id="F13365506"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (dose related; 15% to 32%), drowsiness (dose related; 15% to 27%), fatigue (13% to 16%), confusion (dose related; 4% to 16%), ataxia (dose related; 5% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (dose related; 10% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">2% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Vertigo (8% to 9%), memory impairment (dose related; 6% to 9%), dysarthria (2% to 8%), lack of concentration (6% to 7%), aphasia (dose related; 1% to 7%), abnormal gait (dose related; 2% to 6%), disorientation (5%), anxiety (3% to 5%), equilibrium disturbance (dose related; 3% to 5%), paresthesia (3% to 5%), amnesia (3%), dysphasia (1% to 3%), hallucination (≤2%), psychotic symptoms (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin discoloration (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (dose related; 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (6% to 9%), constipation (dose related; 4% to 5%), dyspepsia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (dose related; 1% to 4%), urinary hesitancy (1% to 4%), urine discoloration (dose related; 2% to 3%), urinary retention (≤2%), hematuria (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (dose related; 4% to 10%), diplopia (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (mean: 7.7 msec), syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Brain disease, coma, euphoria</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Nystagmus, retinal pigment changes</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis, renal colic</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;2%, postmarketing, and/or case reports: Dysphagia, hydronephrosis, hyperhidrosis, hypokinesia, increased appetite, increased liver enzymes, maculopathy (acquired vitelliform lesions), malaise, mucosal discoloration, myoclonus, nail discoloration, ocular discoloration (sclera), peripheral edema, suicidal ideation, suicidal tendencies, xerostomia</p></div>
<div class="block coi drugH1Div" id="F13365450"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F13365451"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Dose-related dizziness and somnolence (generally mild-to-moderate) have been reported; effects generally occur during dose titration and appear to diminish with continued use. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic effects: Skin discoloration has been reported; typically blue in color (but may also be gray-blue or brown) and is predominantly located on or around the lips, nail beds of the fingers or toes, face and legs; discoloration of the palate, sclera, and conjunctiva may also occur. Skin discoloration developed in ~10% of patients, generally after ≥2 years of treatment and at higher doses (≥900 mg). If detected, consider other treatment options or discontinue use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric disorders: Dose-related neuropsychiatric disorders, including confusion, psychotic symptoms, and hallucinations, have been reported, generally within the first 8 weeks of treatment; some patients required hospitalization. Symptoms resolved in most patients within 7 days of discontinuation of therapy. The risk appears to be greatest with rapid titration at greater than the recommended doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular complications: <b> [US Boxed Warning]: Retinal abnormalities that may progress to vision loss have been reported and were seen in about one-third of patients after approximately 4 years of treatment. These retinal abnormalities exhibited funduscopic features similar to those of retinal pigment dystrophies. Macular abnormalities characterized as vitelliform lesions have also been observed; these lesions have been identified most consistently with optical coherence tomography imaging. The rate of progression and reversibility of these retinal abnormalities is unknown. Reversibility of retinal pigmentary abnormalities and partial resolution of vitelliform lesions has been reported after discontinuation of ezogabine. Limit use to patients who have responded inadequately to other treatments and in whom the benefits of therapy exceed the risk of vision loss. Visual monitoring (at least visual acuity, dilated fundus photography, and optical coherence tomography) by an ophthalmic professional is recommended at baseline and at 6-month intervals. Other visual tests may include fluorescein angiograms, perimetry, and electroretinograms). Discontinue use if there is no substantial benefit after adequate titration or if retinal pigmentary abnormalities or vision changes are detected. If no other treatment options are available and the benefits of treatment outweigh the potential risk of vision loss, then may cautiously continue treatment with ezogabine. </b></p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QT prolongation has been observed; monitor ECG in patients with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), concomitant medications which may augment QT prolongation, or any underlying cardiac abnormality which may also potentiate risk (eg, heart failure, ventricular hypertrophy).</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal thinking/behavior: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention: Urinary retention, including retention requiring catheterization, has been reported, generally within the first 6 months of treatment. All patients should be monitored for urologic symptoms; close monitoring is recommended in patients with other risk factors for urinary retention (eg, benign prostatic hyperplasia), patients unable to communicate clinical symptoms, or patients who use concomitant medications that may affect voiding (eg, anticholinergics).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Dosage adjustment recommended in moderate to severe hepatic impairment; ezogabine exposure increases in moderate to severe impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Dosage adjustment recommended in patients with CrCl &lt;50 mL/minute renal impairment or patients with end-stage renal disease receiving hemodialysis; ezogabine undergoes significant renal elimination.</p>
<p style="text-indent:-4em;margin-left:4em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use caution in elderly due to potential for urinary retention, particularly in older men with symptomatic BPH. Systemic exposure is increased in the elderly; dosage adjustment is recommended in patients ≥65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency. Unless safety concerns require a more rapid withdrawal, therapy should be withdrawn gradually over a period of ≥3 weeks to minimize the potential of increased seizure frequency.</p></div>
<div class="block prod-avail drugH1Div" id="F48828700"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Potiga has been discontinued in the US for more than 1 year.</p></div>
<div class="block geq drugH1Div" id="F14274793"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322905"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Potiga Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (90): $651.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (90): $1303.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (90): $1303.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (90): $1303.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F14263398"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-V</p></div>
<div class="block adm drugH1Div" id="F13371904"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer in 3 equally divided doses daily with or without food. Swallow tablets whole; do not break, crush, dissolve, or chew. If therapy is discontinued, gradually reduce dose over at least 3 weeks unless safety concerns require abrupt withdrawal.</p></div>
<div class="block meg drugH1Div" id="F13365443"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Potiga/pdf/POTIGA-MG.PDF, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F12915694"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Partial-onset seizures:</b> As adjunctive treatment for partial-onset seizures in patients ≥18 years who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity</p></div>
<div class="block mst drugH1Div" id="F13365441"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ezogabine may be confused with ezetimibe.</p>
<p style="text-indent:-2em;margin-left:4em;">Potiga may be confused with Portia</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F21122191"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F21122189"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Ezogabine. Alcohol (Ethyl) may increase the serum concentration of Ezogabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Ezogabine. Management: Consider increasing the ezogabine dose when adding carbamazepine.  Monitor patients using the combination closely for evidence of adequate ezogabine therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of Ezogabine. Management: Consider increasing the ezogabine dose when adding phenytoin.  Patients using this combination should be monitored closely for evidence of adequate ezogabine therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Ezogabine may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F13365447"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to ezogabine during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F13365449"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if ezogabine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made to continue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.  </p></div>
<div class="block mop drugH1Div" id="F13371907"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Seizures; electrolytes, bilirubin, QT interval (in patients with risk factors for QT prolongation), renal and hepatic function; urologic symptoms; observe patient for excessive sedation, confusion, psychotic symptoms, and hallucinations; suicidality (eg, suicidal thoughts, depression, behavioral changes); skin discoloration (blue, or gray-blue or brown in color) around the lips, nail beds of fingers or toes, face and legs.</p>
<p style="text-indent:0em;margin-top:2em;">Ophthalmic exams (at least visual acuity testing, dilated fundus photography, and optical coherence tomography) at baseline and 6-month intervals; fluorescein angiograms, optical coherence tomography, perimetry, and electroretinograms may also be considered.</p></div>
<div class="block pha drugH1Div" id="F13365970"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ezogabine binds the KCNQ (Kv7.2-7.5) voltage-gated potassium channels, thereby stabilizing the channels in the open formation and enhancing the M-current.  As a result, neuronal excitability is regulated and epileptiform activity is suppressed. In addition, ezogabine may also exert therapeutic effects through augmentation of GABA-mediated currents.</p></div>
<div class="block phk drugH1Div" id="F13371878"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 2 to 3 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Ezogabine: ~80%; N-acetyl active metabolite (NAMR): ~45% </p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Glucuronidation via UGT1A4, UGT1A1, UGT1A3, and UGT1A9 and acetylation via NAT2 to an N-acetyl active metabolite (NAMR) and other inactive metabolites (eg, N-glucuronides, N-glucoside)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~60%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Ezogabine and NAMR: 7 to 11 hours; increased by ~30% in elderly patients</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 0.5 to 2 hours; delayed by 0.75 hours when administered with high-fat food</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~85%, 36% of total dose as unchanged drug, 18% of total dose as NAMR); feces (~14%, 3% of total dose as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51154126"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The AUC was increased by ~30% in patients with mild renal impairment and doubled in patients with moderate impairment to ESRD (CrCl &lt;50 mL/minute) relative to healthy subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The AUC was increased by ~50% in subjects with moderate hepatic impairment and doubled in subjects with severe hepatic impairment. There was an increase of ~30% in exposure to NAMR in patients with moderate to severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The AUC was ~40% to 50% higher and terminal half-life was prolonged by ~30% in elderly patients compared with younger subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: The AUC values were ~20% higher in younger females compared with younger males and ~30% higher in elderly women compared with elderly men. The C<sub>max</sub> values were ~50% higher in younger females compared with younger males and ~100% higher in elderly women compared with elderly men.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059493"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Potiga</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Trobalt</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20944074">
<a name="20944074"></a>Brodie MJ, Lerche H, Gil-Nagel A, et al, “Efficacy and Safety of Adjunctive Ezogabine (Retigabine) In Refractory Partial Epilepsy,” <i>Neurology</i>, 2010, 75(20:1817-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezogabine-retigabine-united-states-not-available-drug-information/abstract-text/20944074/pubmed" id="20944074" target="_blank">20944074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11831540">
<a name="11831540"></a>Ferron GM, Paul J, Fruncillo R, et al, “Multiple-Dose, Linear, Dose-Proportional Pharmacokinetics of Retigabine in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(2):175-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezogabine-retigabine-united-states-not-available-drug-information/abstract-text/11831540/pubmed" id="11831540" target="_blank">11831540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21451152">
<a name="21451152"></a>French JA, Abou-Khalil BW, Leroy RF, et al, “Randomized, Double-Blind, Placebo-Controlled Trial of Ezogabine (Retigabine) in Partial Epilepsy,” <i>Neurology</i>, 2011, 76(18):1555-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezogabine-retigabine-united-states-not-available-drug-information/abstract-text/21451152/pubmed" id="21451152" target="_blank">21451152</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Potiga (ezogabine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21254787">
<a name="21254787"></a>Stephen LJ and Brodie MJ, “Pharmacotherapy of Epilepsy: Newly Approved and Developmental Agents,” <i>CNS Drugs</i>, 2011, 25(2):89-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezogabine-retigabine-united-states-not-available-drug-information/abstract-text/21254787/pubmed" id="21254787" target="_blank">21254787</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16789 Version 220.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
